From: Esophageal papillomatosis: an exceedingly rare disease
 | Source | Methods | Outcome |
---|---|---|---|
Medicine | Â | Â | Â |
PPI | Pasman et al. [37] | N | Inefficacy |
 | Gencdal et al. [68] | N | Improvement of symptoms |
Alpha-interferon | Hording et al. [25] | 4 MIU daily, subcutaneously for 4Â weeks, double dose for 2Â weeks, 8 MIU three times weekly | Early improvement and subsequent recurrence |
 | Van Cutsem et al. [26] | 6 × 106 U five times a week for 4 weeks followed by three times a week for 2 months | Recurrence |
Vacine | Mészner et al. [7] | Three doses of the quadrivalent HPV vaccine at 0, 2 and 6 months | Elimination |
Endoscopy | Â | Â | Â |
APC | Pasman et al. [37] | ERBE VIO APC system,with an effect of 5 | Elimination |
Radiofrequency ablation | Romano et al. [28] | The first procedure treatment: the 360° catheter; the second and third treatment: the Barrx Channel catheter at 12 J/cm2 | Elimination |
Photodynamic therapy | Wolfsen et al. [43] | Infusion of porfimer sodium (2 mg/kg), with endoscopic delivery of 300–400 J/cm fifiber length red light energy (wavelength 630 nm) | Remission |
Cryotherapy | McDonald et al. [62] | Liquid nitrogen cryotherapy | Elimination |
 | Alomari et al. [66] | Liquid nitrogen cryogen applied for 20 s, 3 sessions, 2–4 months apart | Elimination |
Laser therapy | Hording et al. [25] | CO2-laser: 4 times | Inefficacy |
 | Tu et al. [65] | Nd:YAG:50 watts, 0.2 s duration, and 0.1 s intervals | Elimination |
Local injections of HPMPC cytosine | Van Cutsem et al. [26] | HPMPC 1.25 mg/kg, the first four injections: an interval of 1 week, the next three injections: an interval of 3–5 weeks | Elimination |
EMR | Kim et al. [67] | Performed by a band mucosectomy device | Elimination |
Dilation | Narayani et al. [14] | Progressive dilation | Temporary improvement and subsequent progression |
Saravanan et al. [15] | Repeated dilation | ||
Kao et al. [52] | Repeated dilation |